- cafead Jan 08, 2021 at 10:02: AM
via Investors like to see big plans, and Kevin Judice has plenty. The DiCE Molecules CEO is plotting a clinical trial launch for the biotech’s lead small molecule for psoriasis and wants to double the staff in the next year and a half.
On Friday, those big plans landed him an $80 million Series C round.
article source
On Friday, those big plans landed him an $80 million Series C round.
article source